POA Pharma GmbH
Daring to be extraordinary to benefit the health of all generations
POA – Daring to be extraordinary for you
POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.
Founded in 2023, we are committed to doing all we can to improve the lives and benefit the health of all generations affected by a variety of diseases.
POA Pharma network
POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.
Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.
Galen Limited (Northern Ireland)
POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, we are positioned to distribute products worldwide.
Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group.
With 7000+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.
Medical Nutrition
In October 2023, POA Pharma GmbH introduced its first products to benefit patients with metabolic diseases, including PKU, for the German IMD community.
In celebration of the launch in Germany, POA Pharma GmbH presented scholarships for two German applicants through the 2023 Medical Nutrition Scholarship Award programme.
Corporate Social Responsibility
The strategy and activities outlined within this report demonstrate our organisation’s current and future commitment to long-term corporate sustainability and positive corporate impact.
Our strategy aims to maximise our efficiencies and promote fair and sustainable business practices, while ensuring we continue to prioritise initiatives with the greatest impact on human health.
Latest News
POA Pharma GmbH announces Medical Nutrition Scholarship Winners for 2024
25 Oct 2024
POA Pharma GmbH, a pharmaceutical company based in Sprockhövel, successfully ran its Medical Nutrition Scholarship for the second year. This year, the scholarship extended the [...]
POA Pharma announces expansion into Austria, deepening its inborn metabolic disease footprint in Europe
30 May 2024
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced the launch of PKU Easy Microtabs Plus in [...]
POA Pharma Interview with Hamburger Kaffeeklatsch’s Johannes Röhr
15 Mar 2024
In the March 2024 issue of the German PKU related newspaper 'Hamburger Kaffeeklatsch', Johannes Röhr interviews POA Pharma about its company mission and PKU [...]
